Mirae Asset Global Investments Co. Ltd. Acquires 1,821 Shares of STAAR Surgical (NASDAQ:STAA)

Mirae Asset Global Investments Co. Ltd. raised its holdings in STAAR Surgical (NASDAQ:STAA) by 8.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,679 shares of the medical instruments supplier’s stock after buying an additional 1,821 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in STAAR Surgical were worth $708,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Clear Street Markets LLC bought a new stake in STAAR Surgical in the third quarter valued at approximately $29,000. Nisa Investment Advisors LLC increased its stake in shares of STAAR Surgical by 415.8% during the third quarter. Nisa Investment Advisors LLC now owns 2,445 shares of the medical instruments supplier’s stock worth $98,000 after purchasing an additional 1,971 shares during the period. Covestor Ltd increased its stake in shares of STAAR Surgical by 82,466.7% during the third quarter. Covestor Ltd now owns 2,477 shares of the medical instruments supplier’s stock worth $100,000 after purchasing an additional 2,474 shares during the period. Van ECK Associates Corp increased its stake in shares of STAAR Surgical by 44.5% during the third quarter. Van ECK Associates Corp now owns 3,184 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 980 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in shares of STAAR Surgical by 171.5% during the third quarter. PNC Financial Services Group Inc. now owns 3,755 shares of the medical instruments supplier’s stock worth $151,000 after purchasing an additional 2,372 shares during the period. Institutional investors own 96.70% of the company’s stock.

Insider Buying and Selling at STAAR Surgical

In related news, Director Aimee S. Weisner purchased 1,750 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was acquired at an average price of $38.11 per share, for a total transaction of $66,692.50. Following the purchase, the director now owns 10,864 shares of the company’s stock, valued at $414,027.04. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, April 4th. Piper Sandler lowered their target price on STAAR Surgical from $40.00 to $33.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 27th. William Blair upgraded STAAR Surgical from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 4th. Mizuho raised their price objective on STAAR Surgical from $45.00 to $53.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Finally, Stifel Nicolaus restated a “buy” rating and set a $50.00 price objective on shares of STAAR Surgical in a research note on Monday, April 1st. Seven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, STAAR Surgical has an average rating of “Hold” and a consensus price target of $46.38.

STAAR Surgical Stock Down 0.8 %

NASDAQ STAA opened at $47.82 on Thursday. STAAR Surgical has a twelve month low of $26.66 and a twelve month high of $73.13. The company has a market cap of $2.34 billion, a price-to-earnings ratio of 111.21 and a beta of 0.86. The business’s fifty day moving average is $38.87 and its 200 day moving average is $35.51.

STAAR Surgical (NASDAQ:STAA) last posted its quarterly earnings data on Monday, February 26th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.01). STAAR Surgical had a return on equity of 8.73% and a net margin of 6.62%. The business had revenue of $76.27 million during the quarter, compared to the consensus estimate of $75.94 million. During the same period last year, the business posted $0.04 earnings per share. The business’s revenue was up 19.1% on a year-over-year basis. On average, research analysts anticipate that STAAR Surgical will post 0.03 earnings per share for the current fiscal year.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.